BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35080602)

  • 1. Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence.
    Sivanesan S; Taskén KA; Grytli HH
    JAMA Netw Open; 2022 Jan; 5(1):e2145230. PubMed ID: 35080602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
    Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
    BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA
    Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
    Trock BJ; Han M; Freedland SJ; Humphreys EB; DeWeese TL; Partin AW; Walsh PC
    JAMA; 2008 Jun; 299(23):2760-9. PubMed ID: 18560003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.
    Kattan MW; Wheeler TM; Scardino PT
    J Clin Oncol; 1999 May; 17(5):1499-507. PubMed ID: 10334537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
    Hackman G; Taari K; Tammela TL; Matikainen M; Kouri M; Joensuu T; Luukkaala T; Salonen A; Isotalo T; Pétas A; Hendolin N; Boström PJ; Aaltomaa S; Lehtoranta K; Hellström P; Riikonen J; Korpela M; Minn H; Kellokumpu-Lehtinen PL; Pukkala E; Hemminki A;
    Eur Urol; 2019 Nov; 76(5):586-595. PubMed ID: 31375279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
    Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
    JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
    Murtola TJ; Kujala PM; Tammela TL
    Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.
    Lyon TD; Turner RM; Yabes JG; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
    Urology; 2016 Nov; 97():153-159. PubMed ID: 27516122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of radical prostatectomy for prostate cancer from a single institution].
    Ishida R; Kobayashi H; Yoshida S; Ogawa M; Shiota T; Nishikimi T; Yamada H; Yokoi K
    Nihon Hinyokika Gakkai Zasshi; 2009 Sep; 100(6):615-24. PubMed ID: 19827538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy.
    Cooperberg MR; Freedland SJ; Pasta DJ; Elkin EP; Presti JC; Amling CL; Terris MK; Aronson WJ; Kane CJ; Carroll PR
    Cancer; 2006 Nov; 107(10):2384-91. PubMed ID: 17039503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of progression after PSA elevation following radical prostatectomy.
    Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
    JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    JAMA; 2005 Jul; 294(4):433-9. PubMed ID: 16046649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.